POSTER: Phase 1/2 Trial of Oral EPI-7386 (masofaniten) in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects mCRPC: Current Phase 1 (P1) Results

Background The androgen receptor (AR) is activated by androgen binding to the ligand binding domain (LBD) which induces the dimerization and nuclear translocation of the AR. Current AR-targeted therapies work directly or indirectly through the LBD of the AR either by competing with androgen binding to the LBD (lutamide) or by inhibiting the androgen production (centrally or through CYP17 inhibition).